Developer docs
API playgroundTry for free, no card

Search company profiles

Peptron, Inc.

Full company profile

uuid0053cga

Namestring
Peptron, Inc.
Legal namestring
Peptron, Inc.
Websiteurl
peptron.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Peptron, Inc. is a Korean biopharmaceutical company founded in 1997 and headquartered in Daejeon, Republic of Korea. The company is built around SmartDepot™, a proprietary ultrasonic spray drying technology that produces uniformly sized sustained-release (SR) injectable microsphere formulations of peptide and small molecule drugs. The platform enables release profiles ranging from one week to six months without chemical modification of the active pharmaceutical ingredient, avoids toxic organic solvents (methylene chloride, N-methylpyrrolidone, methanol), and produces microspheres small enough for 27–30G needles with sub-10-second reconstitution. Over 90 international patents protect the platform, and an in-house GMP manufacturing facility at Osong Bio Park produces more than 48,000 vials of SR-exenatide per month across 16,378 square meters.

The company's pipeline spans endocrine, metabolic, neurological, and oncology indications. Commercial-stage and near-commercial assets include LEUPONE™ (leuprorelin acetate 3.75 mg depot), which received Korean MFDS approval in July 2025 and was launched in October 2025, and Luphere® Depot (SR-leuprolide), licensed to Daewoong Pharmaceuticals. Clinical assets include PT320 (SR-exenatide for Parkinson's disease with IND-approved Phase 2), PT302 (SR-exenatide for Type 2 diabetes, Phase 2 completed), PT403 (SR-semaglutide) and PT404 (SR-tirzepatide) for diabetes/obesity, PT201 (SR-octreotide for acromegaly with completed Canadian bioequivalence study), and PAb 001, a first-in-class OT-MUC1 targeting antibody for multiple MUC1+ cancers. Peptron also operates a custom peptide synthesis service, supplying over 500 research organizations across more than 30 countries.

Peptron's business model rests on three revenue streams: (1) product licensing and royalties from partners such as Daewoong, LG Chem, Yuhan Corporation, and Penmix; (2) co-development partnerships where pharmaceutical companies fund clinical development and provide market access; and (3) contract peptide synthesis services sold directly to universities, hospitals, and research institutes, with US customer service handled through CRM Consulting Group in Gaithersburg, Maryland. The company has been publicly listed on KOSDAQ since July 2015 and maintains approximately 15 employees across its headquarters, manufacturing, Seoul, and US offices.

Short descriptiontext

Peptron, Inc. is a Korean biopharmaceutical company that develops sustained-release injectable drug formulations using its proprietary SmartDepot™ ultrasonic spray drying technology. It licenses its platform and pipeline products—including LEUPONE™, PT320, and GLP-1 therapies—to global pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDaejeon, South Korea
HQ citystring
Daejeon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sustained-release drug delivery, injectable microsphere formulations, custom peptide synthesis, long-acting injectable pharmaceuticals, ultrasonic spray drying technology
Industry4 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceutical Drug Delivery & Sustained-Release Injectables
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Peptide Synthesis Services
TypeOne Time License
Description

Custom peptide synthesis services provided to universities, hospitals, and research institutes globally. Services include various modifications, purities, and quantities with quality control (ISO 9001 certified).

peptron.com
2Product Licensing and Royalties
TypeLicensing Royalties
Description

Licensing out proprietary formulations and technologies to pharmaceutical partners. Includes technology transfer, joint commercialization agreements, and royalty streams from marketed products (Luphere® Depot, LEUPONE™).

peptron.com
3Co-development Partnerships
TypeProfessional Services
Description

Joint development agreements with pharmaceutical partners for clinical development and commercialization of sustained-release formulations. Partners provide development funding and market access.

peptron.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details1 tier
1Custom Peptide Synthesis - Quotation-based pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing based on amino acid sequence, quantity, purity level, and modifications requested. Customers submit quotation requests through online form or email.

peptron.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1SmartDepot™
Description

Proprietary ultrasonic spray drying technology for the preparation of sustained release (SR) injectable microsphere formulation of drug

peptron.com
+3 more records
Core offering1 text field

Peptron develops and manufactures sustained-release injectable drug formulations using its proprietary SmartDepot™ ultrasonic spray drying platform, with marketed and clinical-stage products targeting neurodegenerative diseases (PT320 for Parkinson's), metabolic disorders (PT302, PT403, PT404 for diabetes/obesity), oncology (PAb 001), endocrine disorders (LEUPONE™, Luphere® Depot, PT201), and provides custom peptide synthesis services to research institutions worldwide. The company monetizes through pharmaceutical product licensing, co-development partnerships with major pharma companies, and contract research/manufacturing services.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Peptron, Inc. is a pharmaceutical company developing sustained-release drug delivery technologies and therapeutics. The company's core platform is SmartDepot™, an ultrasonic spray drying technology for preparing sustained-release injectable microsphere formulations. The product portfolio includes: LEUPONE™ (leuprorelin depot for precocious puberty, launched 2025), PT320 (SR-exenatide for Parkinson's disease in Phase 2), PT403/PT404 (long-acting GLP-1 therapies for diabetes and obesity), PT302 (SR-exenatide for Type 2 diabetes, Phase 2 completed), PAb 001 (novel cancer therapeutic antibody), and PT201 (SR-octreotide for acromegaly). The company also offers contract peptide synthesis services. Business model combines proprietary technology licensing with partnered development and manufacturing under GMP facilities in Osong, Korea.

Product and service10 records
1SmartDepot™ Technology Platform
CategoryDrug Delivery Technology Platform
Description

Proprietary ultrasonic spray drying technology for the preparation of sustained-release injectable microsphere formulations of peptide and small molecule drugs. Enables release profiles from 1 week to 6 months, uses no toxic organic solvents, supports smaller needle sizes, and reconstitutes in under 10 seconds. Available for licensing and co-development with pharmaceutical partners.

2LEUPONE™ (Leuprorelin Acetate 3.75 mg Depot)
CategoryPharmaceutical Product (GnRH Agonist)
Description

Once-monthly leuprorelin acetate depot injection for the treatment of precocious puberty and prostate cancer. Distributed in Korea by LG Chem under an exclusive commercialization agreement. First and only leuprorelin acetate 3.75 mg depot in South Korea with proven bioequivalence to the reference product.

3PT320 (SR-Exenatide for Parkinson's Disease)
CategoryPharmaceutical Product (SR GLP-1 Agonist)
Description

Sustained-release exenatide formulation developed as a potential disease-modifying treatment for Parkinson's Disease via GLP-1 receptor agonist mechanism. IND approval received for Phase 2 clinical trial in South Korea. Developed under exclusive worldwide license to NIH patents for exenatide in neurodegenerative disorders.

4PT403 (SR-Semaglutide for Type 2 Diabetes)
CategoryPharmaceutical Product (SR GLP-1 Agonist)
Description

Long-acting once-monthly injectable formulation of semaglutide for Type 2 Diabetes using SmartDepot™ sustained-release technology. Designed to improve patient compliance through reduced dosing frequency and stable efficacy.

5PT404 (SR-Tirzepatide for Type 2 Diabetes and Obesity)
CategoryPharmaceutical Product (SR GLP-1/GIP Agonist)
Description

Long-acting once-monthly injectable formulation of tirzepatide for Type 2 Diabetes and obesity using SmartDepot™ sustained-release technology, offering stable efficacy with reduced dosing frequency.

6PT302 (SR-Exenatide for Type 2 Diabetes)
CategoryPharmaceutical Product (SR GLP-1 Agonist)
Description

Sustained-release exenatide formulation for Type 2 Diabetes. Phase 1 completed in 2011 and Phase 2 completed in 2015 in Korea under collaboration with Yuhan Corporation. Uses glacial acetic acid (non-toxic class 3 solvent), supports smaller gauged needles for reduced injection pain, and is patent-protected through 2028 (or 2027 for South Korea).

7PAb 001 (OT-MUC1 Targeting Monoclonal Antibody)
CategoryPharmaceutical Product (Oncology Biologic)
Description

First-in-class novel therapeutic monoclonal antibody targeting OT-MUC1 for cancer therapy. Designed for MUC1+ cancers including triple-negative breast cancer, non-small cell lung, ovarian, prostate, pancreatic, and colorectal cancers with limited targeted therapy options.

8PT201 (SR-Octreotide for Acromegaly)
CategoryPharmaceutical Product (SR Somatostatin Analog)
Description

Sustained-release octreotide formulation for acromegaly treatment, using a new PLGA-glucose formulation. Bioequivalence study completed in Canada. Penmix serves as commercial manufacturing partner for global markets.

9Luphere® Depot (SR-Leuprolide)
CategoryPharmaceutical Product (GnRH Agonist)
Description

SR-Leuprolide injectable formulation (1-month and 3-month) for prostate cancer treatment. Licensed to Daewoong Pharmaceuticals in 2003 and marketed as a generic product in Korea with proven bioequivalence. Represents Peptron's first SmartDepot™ technology product successfully commercialized from R&D to market.

10Custom Peptide Synthesis Service
CategoryContract Research & Manufacturing Service
Description

Custom peptide synthesis service for universities, hospitals, national research institutes, and pharmaceutical companies. Uses automatic peptide synthesizer (PeptrEX) with various modifications including terminal modification, disulfide bonding, labeling, and special amino acids. Purity options include crude, >70%, >80%, >90%, and >95%. Supplies over 500 organizations in 30+ countries.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1LG Chem
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-11-01
Description

Domestic distribution agreement for 'LeupONE' (Leuprorelin Acetate 3.75mg), a treatment for precocious puberty and prostate cancer. LG Chem has exclusive rights for marketing and sales in South Korea. LEUPONE™ received Korean MFDS approval in July 2025 and launched in October 2025.

peptron.com
2Penmix
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Commercial manufacturing partner for PT201 (SR-Octreotide for acromegaly) in global markets. Peptron is also looking for sales partners in interested markets. Pilot bioequivalence study completed in Canada.

peptron.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-12-01
Description

Cooperative Research And Development Agreement (CRADA) for neurodegenerative drug development. Peptron exclusively licensed NIH patents for exenatide in neurodegenerative diseases. Both NIH and Peptron collaborate on additional research to enhance exenatide's ability to cross the blood-brain barrier and deliver neuroprotective effects. Partnership has been ongoing since 2014.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Research collaboration on exenatide for Parkinson's disease. Dr. Thomas Foltynie at UCL conducted investigator-initiated trials showing exenatide's clinical efficacy in Parkinson's patients. UCL findings validate Peptron's approach with sustained-release exenatide formulation (PT320).

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2010-01-01
Description

Collaboration during PT302 Phase 1 and 2 clinical studies for Type 2 Diabetes. Yuhan Corporation has sales exclusivity for Korean market during the studies. PT302 showed ideal PK profile, outstanding injectability, and high bioavailability in clinical trials.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2003-08-01
Description

Licensing Agreement on Technology Transfer and Joint commercialization of 1 and 3 month SR-Leuprolide injectable formulations for prostate cancer treatment. Daewoong markets Luphere® Depot as a generic product in Korea with proven bioequivalence. First experience from R&D to commercialization of SmartDepot technology.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty pharma known for long-acting injectables (e.g., ELIGARD® leuprolide) and SR polymer-based drug delivery, directly comparable to Peptron's microsphere-based SR injectable technology.

TypeOthers
Description

Global medical device/injectable delivery company providing injection systems and drug delivery devices, comparable as a downstream ecosystem participant for Peptron's SR injectable products.

TypeEmerging player
Description

Focused on oral and peptide drug delivery, with a complementary long-acting peptide approach (teriparatide), comparable to Peptron's peptide formulation expertise.

TypeRegional player
Description

Korean specialty pharma with sustained-release GLP-1 (efpegerglucagon) and long-acting biologic programs, comparable regional peer with similar sustained-release technology focus.

5Foresee Pharmaceuticals
TypeDirect peer
Description

Taiwan-based specialty pharma developing long-acting injectable formulations (including leuprolide depot and SR peptide products), comparable to Peptron's sustained-release platform and SERM/depot pipeline.

TypeDirect peer
Description

Swedish specialty pharma developing sustained-release injectable formulations using its FluidCrystal® technology, directly comparable to Peptron's SmartDepot™ platform for long-acting peptide and small molecule injectables.

7PeptiDream
TypeEmerging player
Description

Japanese peptide discovery platform using non-standard amino acids and constrained peptides, comparable to Peptron's peptide chemistry capabilities and custom synthesis service.

TypeEmerging player
Description

UK-based company developing sustained-release formulations using polymer-based drug delivery, comparable to Peptron's microsphere SR technology approach.

TypeBroad incumbent
Description

French specialty pharma with Decapeptyl®/Trelstar® (long-acting leuprorelin/triptorelin) franchises, directly comparable to Peptron's LEUPONE™ and Luphere® Depot products.

TypeBroad incumbent
Description

Marketed Bydureon (SR-exenatide) for T2D, the only commercial SR-exenatide product, directly comparable to Peptron's PT302 and PT320 exenatide assets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Peptron, Inc.

Pharmaceutical Drug Delivery & Sustained-Release Injectablespeptron.com

Peptron, Inc. is a Korean biopharmaceutical company that develops sustained-release injectable drug formulations using its proprietary SmartDepot™ ultrasonic spray drying technology. It licenses its platform and pipeline products—including LEUPONE™, PT320, and GLP-1 therapies—to global pharmaceutical partners.

What Peptron, Inc. does

Peptron, Inc. is a Korean biopharmaceutical company founded in 1997 and headquartered in Daejeon, Republic of Korea. The company is built around SmartDepot™, a proprietary ultrasonic spray drying technology that produces uniformly sized sustained-release (SR) injectable microsphere formulations of peptide and small molecule drugs. The platform enables release profiles ranging from one week to six months without chemical modification of the active pharmaceutical ingredient, avoids toxic organic solvents (methylene chloride, N-methylpyrrolidone, methanol), and produces microspheres small enough for 27–30G needles with sub-10-second reconstitution. Over 90 international patents protect the platform, and an in-house GMP manufacturing facility at Osong Bio Park produces more than 48,000 vials of SR-exenatide per month across 16,378 square meters.

The company's pipeline spans endocrine, metabolic, neurological, and oncology indications. Commercial-stage and near-commercial assets include LEUPONE™ (leuprorelin acetate 3.75 mg depot), which received Korean MFDS approval in July 2025 and was launched in October 2025, and Luphere® Depot (SR-leuprolide), licensed to Daewoong Pharmaceuticals. Clinical assets include PT320 (SR-exenatide for Parkinson's disease with IND-approved Phase 2), PT302 (SR-exenatide for Type 2 diabetes, Phase 2 completed), PT403 (SR-semaglutide) and PT404 (SR-tirzepatide) for diabetes/obesity, PT201 (SR-octreotide for acromegaly with completed Canadian bioequivalence study), and PAb 001, a first-in-class OT-MUC1 targeting antibody for multiple MUC1+ cancers. Peptron also operates a custom peptide synthesis service, supplying over 500 research organizations across more than 30 countries.

Peptron's business model rests on three revenue streams: (1) product licensing and royalties from partners such as Daewoong, LG Chem, Yuhan Corporation, and Penmix; (2) co-development partnerships where pharmaceutical companies fund clinical development and provide market access; and (3) contract peptide synthesis services sold directly to universities, hospitals, and research institutes, with US customer service handled through CRM Consulting Group in Gaithersburg, Maryland. The company has been publicly listed on KOSDAQ since July 2015 and maintains approximately 15 employees across its headquarters, manufacturing, Seoul, and US offices.

Peptron, Inc. firmographics

Firmographics
Name
Peptron, Inc.
Legal name
Peptron, Inc.
Website
https://peptron.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Short description
Peptron, Inc. is a Korean biopharmaceutical company that develops sustained-release injectable drug formulations using its proprietary SmartDepot™ ultrasonic spray drying technology. It licenses its platform and pipeline products—including LEUPONE™, PT320, and GLP-1 therapies—to global pharmaceutical partners.
Ownership category
akta.pro rank

Peptron, Inc. industry classification

Industry
Product category
Pharmaceutical Drug Delivery & Sustained-Release Injectables
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Sustained-release drug delivery
  • Injectable microsphere formulations
  • Custom peptide synthesis
  • Long-acting injectable pharmaceuticals
  • Ultrasonic spray drying technology

Where Peptron, Inc. is headquartered

Location

Headquarters

HQ city
Daejeon
HQ country
South Korea
HQ region
Asia

Offices4 records

Markets served

Peptron, Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Contract Peptide Synthesis Services: Custom peptide synthesis services provided to universities, hospitals, and research institutes globally. Services include various modifications, purities, and quantities with quality control (ISO 9001 certified).
  2. Product Licensing and Royalties: Licensing out proprietary formulations and technologies to pharmaceutical partners. Includes technology transfer, joint commercialization agreements, and royalty streams from marketed products (Luphere® Depot, LEUPONE™).
  3. Co-development Partnerships: Joint development agreements with pharmaceutical partners for clinical development and commercialization of sustained-release formulations. Partners provide development funding and market access.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCustom Peptide Synthesis - Quotation-based pricing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Peptron, Inc. product offering

Product offering

Core offering

Peptron develops and manufactures sustained-release injectable drug formulations using its proprietary SmartDepot™ ultrasonic spray drying platform, with marketed and clinical-stage products targeting neurodegenerative diseases (PT320 for Parkinson's), metabolic disorders (PT302, PT403, PT404 for diabetes/obesity), oncology (PAb 001), endocrine disorders (LEUPONE™, Luphere® Depot, PT201), and provides custom peptide synthesis services to research institutions worldwide. The company monetizes through pharmaceutical product licensing, co-development partnerships with major pharma companies, and contract research/manufacturing services.

Product overview

Peptron, Inc. is a pharmaceutical company developing sustained-release drug delivery technologies and therapeutics. The company's core platform is SmartDepot™, an ultrasonic spray drying technology for preparing sustained-release injectable microsphere formulations. The product portfolio includes: LEUPONE™ (leuprorelin depot for precocious puberty, launched 2025), PT320 (SR-exenatide for Parkinson's disease in Phase 2), PT403/PT404 (long-acting GLP-1 therapies for diabetes and obesity), PT302 (SR-exenatide for Type 2 diabetes, Phase 2 completed), PAb 001 (novel cancer therapeutic antibody), and PT201 (SR-octreotide for acromegaly). The company also offers contract peptide synthesis services. Business model combines proprietary technology licensing with partnered development and manufacturing under GMP facilities in Osong, Korea.

Differentiator

Problem solved

Functional benefit

Brands

  • SmartDepot™: Proprietary ultrasonic spray drying technology for the preparation of sustained release (SR) injectable microsphere formulation of drug
  • LEUPONE™
  • Luphere® Depot
  • PT201

Products and services

  • SmartDepot™ Technology Platform Proprietary ultrasonic spray drying technology for the preparation of sustained-release injectable microsphere formulations of peptide and small molecule drugs. Enables release profiles from 1 week to 6 months, uses no toxic organic solvents, supports smaller needle sizes, and reconstitutes in under 10 seconds. Available for licensing and co-development with pharmaceutical partners.
  • LEUPONE™ (Leuprorelin Acetate 3.75 mg Depot) Once-monthly leuprorelin acetate depot injection for the treatment of precocious puberty and prostate cancer. Distributed in Korea by LG Chem under an exclusive commercialization agreement. First and only leuprorelin acetate 3.75 mg depot in South Korea with proven bioequivalence to the reference product.
  • PT320 (SR-Exenatide for Parkinson's Disease) Sustained-release exenatide formulation developed as a potential disease-modifying treatment for Parkinson's Disease via GLP-1 receptor agonist mechanism. IND approval received for Phase 2 clinical trial in South Korea. Developed under exclusive worldwide license to NIH patents for exenatide in neurodegenerative disorders.
  • PT403 (SR-Semaglutide for Type 2 Diabetes) Long-acting once-monthly injectable formulation of semaglutide for Type 2 Diabetes using SmartDepot™ sustained-release technology. Designed to improve patient compliance through reduced dosing frequency and stable efficacy.
  • PT404 (SR-Tirzepatide for Type 2 Diabetes and Obesity) Long-acting once-monthly injectable formulation of tirzepatide for Type 2 Diabetes and obesity using SmartDepot™ sustained-release technology, offering stable efficacy with reduced dosing frequency.
  • PT302 (SR-Exenatide for Type 2 Diabetes) Sustained-release exenatide formulation for Type 2 Diabetes. Phase 1 completed in 2011 and Phase 2 completed in 2015 in Korea under collaboration with Yuhan Corporation. Uses glacial acetic acid (non-toxic class 3 solvent), supports smaller gauged needles for reduced injection pain, and is patent-protected through 2028 (or 2027 for South Korea).
  • PAb 001 (OT-MUC1 Targeting Monoclonal Antibody) First-in-class novel therapeutic monoclonal antibody targeting OT-MUC1 for cancer therapy. Designed for MUC1+ cancers including triple-negative breast cancer, non-small cell lung, ovarian, prostate, pancreatic, and colorectal cancers with limited targeted therapy options.
  • PT201 (SR-Octreotide for Acromegaly) Sustained-release octreotide formulation for acromegaly treatment, using a new PLGA-glucose formulation. Bioequivalence study completed in Canada. Penmix serves as commercial manufacturing partner for global markets.
  • Luphere® Depot (SR-Leuprolide) SR-Leuprolide injectable formulation (1-month and 3-month) for prostate cancer treatment. Licensed to Daewoong Pharmaceuticals in 2003 and marketed as a generic product in Korea with proven bioequivalence. Represents Peptron's first SmartDepot™ technology product successfully commercialized from R&D to market.
  • Custom Peptide Synthesis Service Custom peptide synthesis service for universities, hospitals, national research institutes, and pharmaceutical companies. Uses automatic peptide synthesizer (PeptrEX) with various modifications including terminal modification, disulfide bonding, labeling, and special amino acids. Purity options include crude, >70%, >80%, >90%, and >95%. Supplies over 500 organizations in 30+ countries.

Companies that use Peptron, Inc.

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles2 records

Peptron, Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Peptron, Inc. partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • LG ChemcoreChannel Partner/ Reseller/ Distributor · 1 November 2023Domestic distribution agreement for 'LeupONE' (Leuprorelin Acetate 3.75mg), a treatment for precocious puberty and prostate cancer. LG Chem has exclusive rights for marketing and sales in South Korea. LEUPONE™ received Korean MFDS approval in July 2025 and launched in October 2025.
  • PenmixmajorStrategic or Co-development Partner · 1 January 2018Commercial manufacturing partner for PT201 (SR-Octreotide for acromegaly) in global markets. Peptron is also looking for sales partners in interested markets. Pilot bioequivalence study completed in Canada.
  • NIH/NIA (National Institutes of Health, National Institute on Aging)coreStrategic or Co-development Partner · 1 December 2014Cooperative Research And Development Agreement (CRADA) for neurodegenerative drug development. Peptron exclusively licensed NIH patents for exenatide in neurodegenerative diseases. Both NIH and Peptron collaborate on additional research to enhance exenatide's ability to cross the blood-brain barrier and deliver neuroprotective effects. Partnership has been ongoing since 2014.
  • UCL (University College London)majorStrategic or Co-development Partner · 1 January 2014Research collaboration on exenatide for Parkinson's disease. Dr. Thomas Foltynie at UCL conducted investigator-initiated trials showing exenatide's clinical efficacy in Parkinson's patients. UCL findings validate Peptron's approach with sustained-release exenatide formulation (PT320).
  • Yuhan CorporationmajorChannel Partner/ Reseller/ Distributor · 1 January 2010Collaboration during PT302 Phase 1 and 2 clinical studies for Type 2 Diabetes. Yuhan Corporation has sales exclusivity for Korean market during the studies. PT302 showed ideal PK profile, outstanding injectability, and high bioavailability in clinical trials.
  • Daewoong Pharmaceutical Co, Ltd.coreStrategic or Co-development Partner · 1 August 2003Licensing Agreement on Technology Transfer and Joint commercialization of 1 and 3 month SR-Leuprolide injectable formulations for prostate cancer treatment. Daewoong markets Luphere® Depot as a generic product in Korea with proven bioequivalence. First experience from R&D to commercialization of SmartDepot technology.

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Peptron, Inc. competitors and assessment

Company assessment

Direct peers

  • Tolmar Pharmaceuticals: Specialty pharma known for long-acting injectables (e.g., ELIGARD® leuprolide) and SR polymer-based drug delivery, directly comparable to Peptron's microsphere-based SR injectable technology.
  • Foresee Pharmaceuticals: Taiwan-based specialty pharma developing long-acting injectable formulations (including leuprolide depot and SR peptide products), comparable to Peptron's sustained-release platform and SERM/depot pipeline.
  • Camurus: Swedish specialty pharma developing sustained-release injectable formulations using its FluidCrystal® technology, directly comparable to Peptron's SmartDepot™ platform for long-acting peptide and small molecule injectables.

Others

  • Becton, Dickinson and Company (BD): Global medical device/injectable delivery company providing injection systems and drug delivery devices, comparable as a downstream ecosystem participant for Peptron's SR injectable products.

Emerging players

  • Entera Bio: Focused on oral and peptide drug delivery, with a complementary long-acting peptide approach (teriparatide), comparable to Peptron's peptide formulation expertise.
  • PeptiDream: Japanese peptide discovery platform using non-standard amino acids and constrained peptides, comparable to Peptron's peptide chemistry capabilities and custom synthesis service.
  • Midatech Pharma: UK-based company developing sustained-release formulations using polymer-based drug delivery, comparable to Peptron's microsphere SR technology approach.

Regional players

  • Hanmi Pharmaceutical: Korean specialty pharma with sustained-release GLP-1 (efpegerglucagon) and long-acting biologic programs, comparable regional peer with similar sustained-release technology focus.

Broad incumbents

  • Ipsen: French specialty pharma with Decapeptyl®/Trelstar® (long-acting leuprorelin/triptorelin) franchises, directly comparable to Peptron's LEUPONE™ and Luphere® Depot products.
  • AstraZeneca (Bydureon franchise): Marketed Bydureon (SR-exenatide) for T2D, the only commercial SR-exenatide product, directly comparable to Peptron's PT302 and PT320 exenatide assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Peptron, Inc. social profiles

Digital presence

Peptron, Inc. compliance and trust

Trust signal

Compliance2 records

Peptron, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Peptron, Inc. leadership team

Management profile

Number of profiles

Profiles5 records

Peptron, Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Peptron, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Peptron, Inc.

What does Peptron, Inc. do?

Peptron develops and manufactures sustained-release injectable drug formulations using its proprietary SmartDepot™ ultrasonic spray drying platform, with marketed and clinical-stage products targeting neurodegenerative diseases (PT320 for Parkinson's), metabolic disorders (PT302, PT403, PT404 for diabetes/obesity), oncology (PAb 001), endocrine disorders (LEUPONE™, Luphere® Depot, PT201), and provides custom peptide synthesis services to research institutions worldwide. The company monetizes through pharmaceutical product licensing, co-development partnerships with major pharma companies, and contract research/manufacturing services.

Is Peptron, Inc. a public or private company?

Peptron, Inc. is a private company. It is classified as public and is currently operating.

When was Peptron, Inc. founded?

Peptron, Inc. was founded in 1997. It employs 11 to 50 people.

Where is Peptron, Inc. based?

Peptron, Inc. is headquartered in Daejeon, South Korea, in the Asia region.

How does Peptron, Inc. make money?

Three revenue lines are on record. Contract Peptide Synthesis Services are the primary driver. The others are product Licensing and Royalties and co-development Partnerships.

Who are Peptron, Inc.'s main competitors?

Direct peers on record are Tolmar Pharmaceuticals, Foresee Pharmaceuticals and Camurus. Becton, Dickinson and Company (BD) is listed as an others. Emerging players are Entera Bio, PeptiDream and Midatech Pharma. Hanmi Pharmaceutical is listed as a regional player. Broad incumbents are Ipsen and AstraZeneca (Bydureon franchise).

Does Peptron, Inc. have an API?

No public API is recorded for Peptron, Inc..

What industry is Peptron, Inc. in?

Peptron, Inc.'s product category is Pharmaceutical Drug Delivery & Sustained-Release Injectables. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingPeptron Wins South Korean Approval for PT403 Phase 1 Obesity TrialPeptron received South Korean regulatory clearance on Nov. 18, 2026, for a Phase 1 trial of obesity candidate PT403. The trial will assess safety, tolerability, and pharmacokinetics in 22 healthy adults, with completion expected Nov. 30, 2027.NatePeptron Plunges on Lilly Deal; Hanmi Falls 10% Despite Drug Approval[K-Bio Pulse] : 네이트 뉴스Peptron's shares fell 29.94% after its technology evaluation with Eli Lilly for SmartDepot ended without a commercialization agreement. Hanmi's stock dropped 10% despite regulatory approval for its first homegrown GLP-1 obesity drug Efe. HLB affiliates surged after FDA approval of its cholangiocarcinoma drug Ripictu.NaverPeptron Plunges on Lilly Deal; Hanmi Falls 10% Despite Drug Approval[K-Bio Pulse]South Korean pharmaceutical stocks showed mixed performance on Oct. 8, with Peptron plunging 29.94% after its technology evaluation with Eli Lilly ended without a follow-on deal, while Hanmi fell 10% despite approval for its first homegrown GLP-1 obesity drug. HLB Group affiliates surged as U.S. approval of Ripictu eased regulatory uncertainty.NatePlague Scare Lifts Diagnostics; Peptron Plunges[K-bio pulse] : 네이트 뉴스South Korean diagnostic stocks rallied on plague concerns after a Russian researcher's death, though no domestic company has a commercial plague test. Peptron fell 25.8% after its Eli Lilly evaluation ended without a commercial deal, while Hanmi Science rose 14.9% after approval of its homegrown GLP-1 obesity drug.NaverPlague Scare Lifts Diagnostics; Peptron Plunges[K-bio pulse]South Korean diagnostic stocks rallied on a suspected plague exposure in Russia, while Peptron fell after its Eli Lilly technology evaluation ended without a commercial deal. Hanmi Science jumped after approval of its homegrown GLP-1 obesity drug, Efpe.PR NewswirePeptron's PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda's LeuplinPeptron, Inc. announced on November 17 that it successfully established bioequivalence for PT105, a once-a-month injectable Leuprolide generic for treating prostate cancer, breast cancer, endometriosis, and precocious puberty, compared to Takeda's reference drug Leuplin. PT105 represents Korea's first commercialized generic version of Leuplin, a blockbuster drug that achieved $1.34 billion in total sales over 30 years, with Peptron achieving equivalence due to the difficulty in emulating Takeda's manufacturing process and technology. Peptron plans to launch PT105 in the domestic market first, then enter the global market with potential partners, while also developing 3- and 6-month formulations of generic Leuprolide.PR NewswireFür PT105 von Peptron, ein Leuprolid mit verzögerter Wirkstofffreisetzung, wurde die Bioäquivalenz zu Leuplin von Takeda nachgewiesenPeptron, Inc. announced on November 17, 2022, that it successfully demonstrated bioequivalence for PT105, a once-monthly injectable leuprolide with delayed release, compared to Takeda's original drug Leuplin. PT105 is Korea's first commercialized generic of Leuplin using Peptron's SmartDepot technology, indicated for prostate cancer, breast cancer, endometriosis, and precocious puberty. The company plans to launch PT105 in the domestic market first and then expand globally with additional 1-, 3-, and 6-month formulations based on the proven bioequivalence and international standards.